Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option
about
Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the DiseaseEmerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.
P2860
Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 August 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option
@en
Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option.
@nl
type
label
Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option
@en
Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option.
@nl
prefLabel
Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option
@en
Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option.
@nl
P2860
P921
P356
P1476
Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option
@en
P2093
P2860
P304
P356
10.1111/IJCP.12720
P5008
P577
2015-08-25T00:00:00Z
2015-12-01T00:00:00Z